Benjamin Levy, MD

Dr Martin Dietrich provides an overview of how to treat MET exon 14 skipping mutations in non–small cell lung cancer.

Dr Misako Nagasaka reviews clinical trial data presented at ESMO 2021 on therapies for NSCLC harboring HER2 exon 20 mutations.

Dr Fernando Santini explains EGFR exon 20 insertion mutations in NSCLC and the best approaches for treating these cases.

A discussion on EGFR mutations in non-small cell lung cancer and the combination treatment strategies for sensitizing mutations.

A look at the challenges associated with different molecular testing methods and the barriers that patients with non–small cell lung cancer face in getting tested.

A panel of thought leaders describe the optimal sample to use in molecular testing in NSCLC and the appropriate time to perform testing in clinical practice.

Experts in lung cancer explain their views on the critical role of liquid biopsy in molecular testing in non–small cell lung cancer.

Oncologists provide insight into what actionable mutations they look for when they order molecular testing for patients with advanced non-small cell lung cancer.

Ben Levy, Mark Socinski, and Stephen Liu describe the current treatment options for patients with NTRK+ NSCLC. They also summarize recent clinical data for agents that target NTRK.

Mark Socinski and Stephen Liu describe the current treatment options for patients with RET+ NSCLC. They also summarize recent clinical data for agents that target RET.

Ben Levy, Mark Socinski, and Stephen Liu explain the role of a RET alteration in NSCLC and its value as a targetable biomarker.

Ben Levy, Mark Socinski, and Stephen Liu describe the current treatment options for patients with ROS1+ NSCLC. They also summarize recent clinical data for agents that target ROS1.

Ben Levy, Mark Socinski, and Stephen Liu explain the role of a ROS1 alteration in NSCLC and its value as a targetable biomarker.

Ben Levy, Mark Socinski, and Stephen Liu describe the current treatment options for patients with ALK+ NSCLC. They also summarize recent clinical data for ALK inhibitors.

Ben Levy, Mark Socinski, and Stephen Liu explain the role of an ALK alteration in NSCLC and its value as a targetable biomarker.

Ben Levy, Mark Socinski, and Stephen Liu explain the various types of genetic alterations and protein expressions that are targetable in NSCLC and the crucial role of comprehensive genetic testing at the time of diagnosis and at the time of disease progression.

An increased understanding of driver gene alterations in advanced non–small cell lung cancer (NSCLC) has led to the development of targeted therapies that offer improved patient outcomes. Ben Levy, MD; Mark A. Socinski, MD; and Stephen Liu, MD, share their thoughts on the emerging treatment landscape and remaining unmet needs.